Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 5

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 5
---
”), pursuant to the terms of the Merger Agreement and the CVR Agreement. In addition, several convertible loans issued to Kadimastem will be converted into equity securities of Kadimastem upon Closing, including (1) a loan to NLS from certain lenders, including Alpha Capital Anstalt, in the amount of $1.7million; and (2) a loan from Michel Revel in the amount of NIS 3.4million. Under the Merger Agreement, any shareholder receiving NLS Common Shares in excess of a 9.99% beneficial ownership limitation as a result of the Merger, shall be issued instead pre -fundedwarrants exercisable for a number of NLS Common Shares equal to such NLS Common Shares in excess of the beneficial ownership limitation, at an exercise price equal to the par value of the NLS Common Shares as of the Effective Time, which, in any event, shall be no less than CHF 0.0001 per share. The Merger Agreement and the consummation of the transactions contemplated thereby have been approved by the NLS Board, and Kadimastem Board and shareholders, and the NLS Board has resolved, subject to customary exceptions, to recommend that the shareholders of the Company approve the Merger Agreement and the transactions contemplated therein. The NLS Common Shares and traded warrants are currently listed on the Nasdaq Capital Market (“Nasdaq”), under the symbols “NLSP” and “NLSPW”, respectively. NLS has filed an additional listing application with Nasdaq, as required by Nasdaq to effect the additional listing of NLS Common Shares issuable in connection with the Merger. NLS has applied to have the common shares of the surviving company trade on the Nasdaq after completion of the Merger, under NLS’s new name, NewcelX Ltd., and new trading symbols for its Common Shares and traded warrants, “NCEL” and “NCELW”, respectively. NLS is holding the NLS Meeting of its shareholders for the following purposes, as more fully described in the accompanying proxy statement: 1.To approve, on an advisory basis, the Merger Agreement. 2.To approve (i) the reduction of the par value from CHF 0.03 per NLS Common Share, per preferred share of the Company (each a “Preferred Share”), and per Preferred Participation Certificate of the Company (each a “PPC”), to (not less than) CHF 0.003 per NLS Common